The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

ENOXIMONE     4-methyl-5-(4- methylsulfanylphenyl) carbony...

Synonyms: Enoximona, Perfane, Enoximonum, Fenoximone, Perfan, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of ENOXIMONE


High impact information on ENOXIMONE


Chemical compound and disease context of ENOXIMONE


Biological context of ENOXIMONE


Anatomical context of ENOXIMONE


Associations of ENOXIMONE with other chemical compounds


Gene context of ENOXIMONE

  • Enoximone (MDL 17,043) for stable, chronic heart failure secondary to ischemic or idiopathic cardiomyopathy [13].
  • To determine whether improved cardiac performance would lower AVP levels, 18 CHF patients received the experimental agent MDL 17,043, with improved cardiac index (1.9 +/- 0.4 to 3.3 +/- 0.7 1 . min-1 . m-2, P less than 0.001) [14].
  • Multifactorial analysis showed that a 50% rise in Cl together with a 50% drop in PCWP, a 50% drop in PVR 30 min after IV E has a high predictive value of survival [15].
  • The effects of enoximone (MDL 17043, Perfan, CAS 77671-31-9) on the activities of the phosphodiesterase (PDE) isoenzymes I-IV and on force of contraction were investigated in ventricular preparations isolated from failing (end-stage myocardial failure, NYHA IV) and non-failing human hearts [16].

Analytical, diagnostic and therapeutic context of ENOXIMONE

  • Quantitative determination of cardiotonic agent MDL 17,043 in plasma by reversed-phase high-performance liquid chromatography [17].
  • To assess the potential positive inotropic properties of the drug MDL 17,043, 10 patients were studied who had impaired left ventricular (LV) performance and who were undergoing diagnostic cardiac catheterization (LV ejection fraction 16 to 46%) [18].
  • MDL 17,043 (0.1-1 mg/kg), administered to anesthetized dogs by intravenous injection, produced dose-related increases in cardiac contractile force lasting more than 1 h [19].


  1. Inotropic therapy for refractory congestive heart failure with oral fenoximone (MDL-17,043): poor long-term results despite early hemodynamic and clinical improvement. Shah, P.K., Amin, D.K., Hulse, S., Shellock, F., Swan, H.J. Circulation (1985) [Pubmed]
  2. Reduction in pulmonary hypertension and in airway resistances by enoximone (MDL 17,043) in decompensated COPD. Leeman, M., Lejeune, P., Melot, C., Naeije, R. Chest (1987) [Pubmed]
  3. Positive inotropic therapy for short-term support and long-term management of patients with congestive heart failure: hemodynamic effects and clinical efficacy of MDL 17,043. Uretsky, B.F., Valdes, A.M., Reddy, P.S. Circulation (1986) [Pubmed]
  4. Effects of new inotropic agents on cyclic nucleotide metabolism and calcium transients in canine ventricular muscle. Endoh, M., Yanagisawa, T., Taira, N., Blinks, J.R. Circulation (1986) [Pubmed]
  5. Comparative effects on hemodynamics of enoximone (MDL 17,043), dobutamine and nitroprusside in severe congestive heart failure. Installé, E., Gonzalez, M., Jacquemart, J.L., Collard, P., Roulette, F., Pourbaix, S., Tremouroux, J. Am. J. Cardiol. (1987) [Pubmed]
  6. Comparison of acute hemodynamic response to dobutamine and intravenous MDL 17,043 (enoximone) in severe congestive heart failure secondary to ischemic cardiomyopathy or idiopathic dilated cardiomyopathy. Likoff, M.J., Ulrich, S., Hakki, A., Iskandrian, A.S. Am. J. Cardiol. (1986) [Pubmed]
  7. Comparative acute hemodynamic effects of intravenous sodium nitroprusside and MDL-17,043, a new inotropic drug with vasodilator effects, in refractory congestive heart failure. Amin, D.K., Shah, P.K., Hulse, S., Shellock, F. Am. Heart J. (1985) [Pubmed]
  8. Mechanisms of improved left ventricular function following intravenous MDL 17,043 in patients with severe chronic heart failure. Kereiakes, D.J., Viquerat, C., Lanzer, P., Botvinick, E.H., Spangenberg, R., Buckingham, M., Parmley, W.W., Chatterjee, K. Am. Heart J. (1984) [Pubmed]
  9. Biochemical studies on the mechanism of cardiotonic activity of MDL 17,043. Kariya, T., Wille, L.J., Dage, R.C. J. Cardiovasc. Pharmacol. (1982) [Pubmed]
  10. Enoximon-echocardiography. A new diagnostic approach for the detection of viable myocardium comparison to dobutamin-echocardiography. Baumgart, D., Buck, T., Leischik, R., Oelert, H., Farahati, J., Reiners, C., Erbel, R. Herz. (1994) [Pubmed]
  11. Simultaneous analysis of a new cardiotonic agent, MDL 17,043, and its major sulfoxide metabolite in plasma by high-performance liquid chromatography. Chan, K.Y., Ohlweiler, D.F., Lang, J.F., Okerholm, R.A. J. Chromatogr. (1984) [Pubmed]
  12. Effects of enoximone and isobutylmethylxanthine on contractile tension and cyclic nucleotide levels in isolated blood-perfused dog papillary muscle. Hsieh, C.P., Kariya, T., Dage, R.C., Ruberg, S.J. J. Cardiovasc. Pharmacol. (1987) [Pubmed]
  13. Enoximone (MDL 17,043) for stable, chronic heart failure secondary to ischemic or idiopathic cardiomyopathy. Weber, K.T., Janicki, J.S., Jain, M.C. Am. J. Cardiol. (1986) [Pubmed]
  14. Plasma vasopressin response to osmotic and hemodynamic stimuli in heart failure. Uretsky, B.F., Verbalis, J.G., Generalovich, T., Valdes, A., Reddy, P.S. Am. J. Physiol. (1985) [Pubmed]
  15. Improved patient selection for TAH implantation. Loisance, D., Dubois Rande, J.L., Deleuze, P., Benvenuti, C., Dervanian, P., Brunet, S., Hillion, M.L., Castaigne, A., Cachera, J.P. ASAIO transactions / American Society for Artificial Internal Organs. (1989) [Pubmed]
  16. Phosphodiesterase inhibition by enoximone in preparations from nonfailing and failing human hearts. Bethke, T., Eschenhagen, T., Klimkiewicz, A., Kohl, C., von der Leyen, H., Mehl, H., Mende, U., Meyer, W., Neumann, J., Rosswag, S. Arzneimittel-Forschung. (1992) [Pubmed]
  17. Quantitative determination of cardiotonic agent MDL 17,043 in plasma by reversed-phase high-performance liquid chromatography. Chan, K.Y., Lang, J.F., Okerholm, R.A. J. Chromatogr. (1983) [Pubmed]
  18. Positive inotropic and vasodilator effects of MDL 17,043 in patients with reduced left ventricular performance. Crawford, M.H., Richards, K.L., Sodums, M.T., Kennedy, G.T. Am. J. Cardiol. (1984) [Pubmed]
  19. Cardiovascular properties of a new cardiotonic agent: MDL 17,043 (1.3-dihydro-4-methyl-5-[4-(methylthio)-benzoyl]-2H-imidazol-2-one). Dage, R.C., Roebel, L.E., Hsieh, C.P., Weiner, D.L., Woodward, J.K. J. Cardiovasc. Pharmacol. (1982) [Pubmed]
WikiGenes - Universities